Dechert represented Abivax in the transaction. Abivax closed its €28 million capital increase. The proceeds of the capital increase, which leading biotech investors in Europe and…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
